Alzheimer's Treatment Decreases Plaques, Improves Cognition

"Antibody-based immunotherapy against Αβ to trigger its clearance or mitigate its neurotoxicity has so far been unsuccessful. Here we report the generation of aducanumab, a human monoclonal antibody that selectively targets aggregated Αβ. In a transgenic mouse model of AD, aducanumab is shown to enter the brain, bind parenchymal Αβ, and reduce soluble and insoluble Αβ in a dose-dependent manner. In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Αβ in a dose- and time-dependent manner. This is accompanied by a slowing of clinical decline measured by Clinical Dementia Rating-Sum of Boxes and Mini Mental State Examination scores."